Cancilico

Cancilico is an artificial intelligence diagnostic company focused on blood cancer. MyeloAID, its AI-based diagnostic software, is built on a data model that relies on a vast amount of verified datasets from various malignant tumors as well as data from healthy individuals. The company is committed to improving patient outcomes and advancing medical research. Its technology not only accelerates the diagnostic process but also significantly enhances accuracy, opening new possibilities for treatment and research. By automating routine tasks, it frees up valuable time for healthcare professionals, enabling them to focus on more complex aspects of patient care.